Diabetes, cardiovascular risk and nephropathy

Cardiology Clinics
Allison J Hahr, Mark E Molitch

Abstract

Diabetic patients with chronic kidney disease are at high risk for cardiovascular disease (CVD). All aspects of risk reduction should be rigorously applied to such patients. Statins should be used with reduction of low-density lipoprotein cholesterol levels, and blood pressure management is important. Glycemic control remains important for reduction in the development and progression of retinopathy, neuropathy, and even nephropathy itself. Reduction of other risk factors, such as smoking cessation and weight reduction, should also be implemented. Multiple risk factor reduction can have a large effect on reduction of CVD outcomes.

References

Jan 4, 1996·The New England Journal of Medicine·M J KlagJ Stamler
Oct 27, 1998·Mayo Clinic Proceedings·T O'BrienB R Zimmerman
Jul 15, 2000·Annals of Internal Medicine·V A Fonseca
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Aug 13, 2004·The New England Journal of Medicine·Pim van der HarstDirk J van Veldhuisen
Sep 11, 2004·Journal of the American College of Cardiology·Scott M GrundyUNKNOWN Coordinating Committee of the National Cholesterol Education Program
Sep 24, 2004·Annals of Internal Medicine·Elizabeth SelvinSherita Hill Golden
Oct 27, 2004·Archives of Internal Medicine·Antonio CerielloJaakko Tuomilehto
Jul 22, 2005·The New England Journal of Medicine·Christoph WannerUNKNOWN German Diabetes and Dialysis Study Investigators
Oct 28, 2005·Journal of the American Society of Nephrology : JASN·Marcello TonelliGary Curhan
Nov 18, 2005·The Journal of Clinical Endocrinology and Metabolism·Henry N Ginsberg
Dec 24, 2005·The New England Journal of Medicine·David M NathanUNKNOWN Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research
Jan 13, 2006·Circulation·Thomas ThomUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Feb 6, 2007·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·UNKNOWN KDOQI
Jun 20, 2007·Annals of Internal Medicine·Edward W GreggCatherine C Cowie
Aug 21, 2007·JAMA : the Journal of the American Medical Association·Sean M DonahoeElliott M Antman
Aug 19, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Mark E Molitch
Jan 10, 2008·Diabetes Care·UNKNOWN American Diabetes Association
Feb 8, 2008·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Dec 19, 2008·The New England Journal of Medicine·William DuckworthUNKNOWN VADT Investigators
Apr 1, 2009·The New England Journal of Medicine·Bengt C FellströmUNKNOWN AURORA Study Group
Jun 9, 2009·The New England Journal of Medicine·UNKNOWN BARI 2D Study GroupBurton E Sobel
Jan 29, 2010·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Citations

Sep 26, 2014·Journal of Medical Economics·John A RizzoJennifer H Lofland
Jan 18, 2012·Journal of Clinical Pharmacology·Jessica L StefflAli J Olyaei
Nov 20, 2012·Clinica Chimica Acta; International Journal of Clinical Chemistry·Caroline Pereira DominguetiAna Paula Fernandes
Aug 18, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Fadia MayyasAnan Jarab
Jun 15, 2017·BioMedicine·Jai-Sing YangFuu-Jen Tsai
Jan 28, 2018·Artificial Cells, Nanomedicine, and Biotechnology·Abdul AhadAbdullah M Al-Mohizea

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.